| scholarly article | Q13442814 |
| P50 | author | Tsuyoshi Yokoi | Q61658900 |
| P2093 | author name string | Akiko Nakamura | |
| Hiroyuki Yamanaka | |||
| Miki Nakajima | |||
| Ryoichi Fujiwara | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1461-1464 | |
| P577 | publication date | 2008-05-14 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines | |
| P478 | volume | 36 |
| Q34237017 | A genome-wide association study identifies UGT1A1 as a regulator of serum cell-free DNA in young adults: The Cardiovascular Risk in Young Finns Study |
| Q34010773 | A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis |
| Q35774129 | A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk |
| Q34067581 | Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15 |
| Q64254474 | An Investigation on Glucuronidation Metabolite Identification, Isozyme Contribution, and Species Differences of GL-V9 In Vitro and In Vivo |
| Q36104912 | Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes |
| Q39442380 | Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis |
| Q28484515 | Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells |
| Q54313392 | Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. |
| Q34730731 | Associations between polymorphisms in glucuronidation and sulfation enzymes and sex steroid concentrations in premenopausal women in the United States |
| Q36905502 | Bioactivation of Heterocyclic Aromatic Amines by UDP Glucuronosyltransferases |
| Q33567159 | Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. |
| Q38357424 | Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer |
| Q34482453 | Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis |
| Q39868674 | Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype |
| Q35226246 | Characterization of dibenzo[a,l]pyrene-trans-11,12-diol (dibenzo[def,p]chrysene) glucuronidation by UDP-glucuronosyltransferases. |
| Q37530912 | Colonic treatments and targets: issues and opportunities |
| Q47628268 | Constitutive expression and phenobarbital modulation of drug metabolizing enzymes and related nuclear receptors in cattle liver and extra-hepatic tissues |
| Q42953780 | Constitutive expression of drug metabolizing enzymes and related transcription factors in cattle testis and their modulation by illicit steroids |
| Q46076879 | Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics |
| Q44952637 | Deglycosylation of liquiritin strongly enhances its inhibitory potential towards UDP-glucuronosyltransferase (UGT) isoforms |
| Q36442232 | Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis |
| Q30425974 | Differential allelic expression of c.1568C > A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3'UTR. |
| Q86824006 | Differential expression of the UGT1A family of genes in stomach cancer tissues |
| Q46370354 | Disturbance of Mammary UDP-Glucuronosyltransferase Represses Estrogen Metabolism and Exacerbates Experimental Breast Cancer |
| Q43129902 | Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10. |
| Q36344087 | Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases |
| Q38714404 | Epigallocatechin-3-gallate augments the therapeutic effects of benzo[a]pyrene-mediated lung carcinogenesis |
| Q35745262 | Expression of UDP-Glucuronosyltransferase 1 (UGT1) and Glucuronidation Activity toward Endogenous Substances in Humanized UGT1 Mouse Brain |
| Q39246454 | Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen |
| Q34557203 | Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term. |
| Q57258718 | Extrahepatic Drug-Metabolizing Enzymes and Their Significance |
| Q38199198 | Extrahepatic metabolism at the body's internal-external interfaces. |
| Q36132293 | First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics |
| Q86230067 | Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine |
| Q34094975 | Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer |
| Q37195375 | Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites |
| Q38746906 | Gene expression study of phase I and II metabolizing enzymes in RPTEC/TERT1 cell line: application in in vitro nephrotoxicity prediction |
| Q38957656 | Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia |
| Q37709526 | Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas? |
| Q50648054 | Glucuronidation and its impact on the bioactivity of [6]-shogaol. |
| Q35745226 | Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10 |
| Q46839004 | Glucuronidation of capsaicin by liver microsomes and expressed UGT enzymes: reaction kinetics, contribution of individual enzymes and marked species differences |
| Q64928374 | Glucuronidation of icaritin by human liver microsomes, human intestine microsomes and expressed UDP-glucuronosyltransferase enzymes: identification of UGT1A3, 1A9 and 2B7 as the main contributing enzymes. |
| Q53029243 | Glucuronidation of macelignan by human liver microsomes and expressed UGT enzymes: identification of UGT1A1 and 2B7 as the main contributing enzymes. |
| Q33714567 | Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases |
| Q44384710 | Glycyrrhetinic acid exhibits strong inhibitory effects towards UDP-glucuronosyltransferase (UGT) 1A3 and 2B7. |
| Q24310887 | Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3 |
| Q36354228 | Identification and validation of microRNAs directly regulating the UDP-glucuronosyltransferase 1A subfamily enzymes by a functional genomics approach |
| Q47724010 | Identification and validation of the microRNA response elements in the 3'-untranslated region of the UDP glucuronosyltransferase (UGT) 2B7 and 2B15 genes by a functional genomics approach. |
| Q48165186 | Identification of UDP-glucuronosyltransferase isoforms involved in hepatic and intestinal glucuronidation of phytochemical carvacrol |
| Q35022246 | Identification of an unintended consequence of Nrf2-directed cytoprotection against a key tobacco carcinogen plus a counteracting chemopreventive intervention. |
| Q42654731 | Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia |
| Q34364347 | Importance of UDP-glucuronosyltransferase 1A1 expression in skin and its induction by UVB in neonatal hyperbilirubinemia |
| Q41660342 | In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes. |
| Q41197296 | In vitro Inhibitory Effects of Andrographis paniculata, Gynura procumbens, Ficus deltoidea, and Curcuma xanthorrhiza Extracts and Constituents on Human Liver Glucuronidation Activity |
| Q37920916 | In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences |
| Q42961853 | In vitro evidence for bakuchiol's influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7. |
| Q42705230 | In vitro glucuronidation kinetics of deoxynivalenol by human and animal microsomes and recombinant human UGT enzymes |
| Q40600601 | In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. |
| Q28080742 | In vivo and in vitro metabolites from the main diester and monoester diterpenoid alkaloids in a traditional chinese herb, the aconitum species |
| Q34995676 | Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast |
| Q33451969 | Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system |
| Q35856276 | Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer |
| Q57825125 | Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans |
| Q38441297 | Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma. |
| Q49832801 | Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro |
| Q34715481 | Metabolic pathways of the camptothecin analog AR-67 |
| Q46715656 | Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1. |
| Q51679305 | Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans. |
| Q38572337 | MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. |
| Q34496694 | Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways |
| Q36576094 | Nicotine regulates the expression of UDP-glucuronosyltransferase (UGT) in humanized UGT1 mouse brain |
| Q36847720 | Non-steroidal anti-inflammatory drugs do not influence the urinary testosterone/epitestosterone glucuronide ratio |
| Q39248794 | Nuclear factor κB down-regulates human UDP-glucuronosyltransferase 1A1: a novel mechanism involved in inflammation-associated hyperbilirubinaemia |
| Q90704733 | Oleanolic Acid and Ursolic Acid Induce UGT1A1 Expression in HepG2 Cells by Activating PXR Rather Than CAR |
| Q33686893 | PDE7B is involved in nandrolone decanoate hydrolysis in liver cytosol and its transcription is up-regulated by androgens in HepG2. |
| Q24294352 | Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples |
| Q58073610 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective |
| Q37677785 | Pilot study demonstrating potential association between breast cancer image-based risk phenotypes and genomic biomarkers |
| Q28487071 | Polymorphic expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal cancer |
| Q90287076 | Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver |
| Q37221922 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen |
| Q34774040 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors |
| Q38990544 | Prediction of drug-induced liver injury using keratinocytes |
| Q34051253 | Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole |
| Q36097980 | Protein kinase Cα and Src kinase support human prostate-distributed dihydrotestosterone-metabolizing UDP-glucuronosyltransferase 2B15 activity |
| Q24633218 | Pulmonary metabolism of resveratrol: in vitro and in vivo evidence |
| Q36174174 | Quantification of Hepatic UDP glucuronosyltransferase 1A splice variant expression and correlation of UDP glucuronosyltransferase 1A1 variant expression with glucuronidation activity |
| Q35675171 | Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. |
| Q51850950 | Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. |
| Q35197861 | Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues |
| Q37575709 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. |
| Q34489142 | Regulated phosphorylation of a major UDP-glucuronosyltransferase isozyme by tyrosine kinases dictates endogenous substrate selection for detoxification |
| Q37603906 | Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p |
| Q37279051 | Regulation of UGT2B Expression and Activity by miR-216b-5p in Liver Cancer Cell Lines |
| Q46498636 | Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. |
| Q28278452 | Resveratrol from transgenic alfalfa for prevention of aberrant crypt foci in mice |
| Q36450835 | Role of extrahepatic UDP-glucuronosyltransferase 1A1: Advances in understanding breast milk-induced neonatal hyperbilirubinemia. |
| Q35888396 | Role of metabolism in the effects of genistein and its phase II conjugates on the growth of human breast cell lines |
| Q43435543 | Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is associated with urinary bladder cancer risk. |
| Q36276855 | SNP discovery, expression and cis-regulatory variation in the UGT2B genes |
| Q36924729 | Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance |
| Q37258318 | Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research |
| Q46109800 | Simulation of chemical metabolism for fate and hazard assessment. V. Mammalian hazard assessment |
| Q46645029 | Species and tissue differences in serotonin glucuronidation |
| Q46273052 | Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans |
| Q28071266 | Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases |
| Q37575653 | Structure-activity relationships of the glucuronidation of flavonoids by human glucuronosyltransferases. |
| Q48737250 | Testicular vs adrenal sources of hydroxy-androgens in prostate cancer |
| Q91719737 | The Fusarium metabolite culmorin suppresses the in vitro glucuronidation of deoxynivalenol |
| Q88968527 | The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling |
| Q33724160 | The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions |
| Q36940977 | The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk |
| Q26801285 | The emerging role of the androgen receptor in bladder cancer |
| Q35176157 | The inverse relationship between bladder and liver in 4-aminobiphenyl-induced DNA damage. |
| Q50073487 | The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors |
| Q37107040 | The use of allelic imbalance to ascertain cis-regulation for human UGT2B7 in vivo |
| Q38261875 | Transcriptional regulation of human UDP-glucuronosyltransferase genes. |
| Q91971773 | UDP-Glycosyltransferase 3A Metabolism of Polycyclic Aromatic Hydrocarbons: Potential Importance in Aerodigestive Tract Tissues |
| Q37309175 | UDP-glucuronosyltransferase 1A compromises intracellular accumulation and anti-cancer effect of tanshinone IIA in human colon cancer cells |
| Q28543502 | UDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of β-lapachone in human colon cancer cells |
| Q42717814 | UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes |
| Q33714575 | UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility |
| Q37663398 | UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues |
| Q34065012 | UGT2B7 is not expressed in normal breast |
| Q55037290 | Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions. |
| Q37007328 | Urinary bladder cancer susceptibility markers. What do we know about functional mechanisms? |
| Q35990861 | mRNA expression of metabolic enzymes in human cornea, corneal cell lines, and hemicornea constructs |
Search more.